Abnormalities in Alternative Splicing of Apoptotic Genes and Cardiovascular Diseases

Apoptosis is required for normal heart development in the embryo, but has also been shown to be an important factor in the occurrence of heart disease. Alternative splicing of apoptotic genes is currently emerging as a diagnostic and therapeutic target for heart disease. This review addresses the in...

Full description

Bibliographic Details
Main Authors:	Dlamini, Zodwa, Tshidino, Shonisani C., Hull, Rodney
Format:	Online
Language:	English
Published:	MDPI 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661875/

id	pubmed-4661875
recordtype	oai_dc
spelling	pubmed-46618752015-12-10 Abnormalities in Alternative Splicing of Apoptotic Genes and Cardiovascular Diseases Dlamini, Zodwa Tshidino, Shonisani C. Hull, Rodney Review Apoptosis is required for normal heart development in the embryo, but has also been shown to be an important factor in the occurrence of heart disease. Alternative splicing of apoptotic genes is currently emerging as a diagnostic and therapeutic target for heart disease. This review addresses the involvement of abnormalities in alternative splicing of apoptotic genes in cardiac disorders including cardiomyopathy, myocardial ischemia and heart failure. Many pro-apoptotic members of the Bcl-2 family have alternatively spliced isoforms that lack important active domains. These isoforms can play a negative regulatory role by binding to and inhibiting the pro-apoptotic forms. Alternative splicing is observed to be increased in various cardiovascular diseases with the level of alternate transcripts increasing elevated in diseased hearts compared to healthy subjects. In many cases these isoforms appear to be the underlying cause of the disease, while in others they may be induced in response to cardiovascular pathologies. Regardless of this, the detection of alternate splicing events in the heart can serve as useful diagnostic or prognostic tools, while those splicing events that seem to play a causative role in cardiovascular disease make attractive future drug targets. MDPI 2015-11-13 /pmc/articles/PMC4661875/ /pubmed/26580598 http://dx.doi.org/10.3390/ijms161126017 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Dlamini, Zodwa Tshidino, Shonisani C. Hull, Rodney
spellingShingle	Dlamini, Zodwa Tshidino, Shonisani C. Hull, Rodney Abnormalities in Alternative Splicing of Apoptotic Genes and Cardiovascular Diseases
author_facet	Dlamini, Zodwa Tshidino, Shonisani C. Hull, Rodney
author_sort	Dlamini, Zodwa
title	Abnormalities in Alternative Splicing of Apoptotic Genes and Cardiovascular Diseases
title_short	Abnormalities in Alternative Splicing of Apoptotic Genes and Cardiovascular Diseases
title_full	Abnormalities in Alternative Splicing of Apoptotic Genes and Cardiovascular Diseases
title_fullStr	Abnormalities in Alternative Splicing of Apoptotic Genes and Cardiovascular Diseases
title_full_unstemmed	Abnormalities in Alternative Splicing of Apoptotic Genes and Cardiovascular Diseases
title_sort	abnormalities in alternative splicing of apoptotic genes and cardiovascular diseases
description	Apoptosis is required for normal heart development in the embryo, but has also been shown to be an important factor in the occurrence of heart disease. Alternative splicing of apoptotic genes is currently emerging as a diagnostic and therapeutic target for heart disease. This review addresses the involvement of abnormalities in alternative splicing of apoptotic genes in cardiac disorders including cardiomyopathy, myocardial ischemia and heart failure. Many pro-apoptotic members of the Bcl-2 family have alternatively spliced isoforms that lack important active domains. These isoforms can play a negative regulatory role by binding to and inhibiting the pro-apoptotic forms. Alternative splicing is observed to be increased in various cardiovascular diseases with the level of alternate transcripts increasing elevated in diseased hearts compared to healthy subjects. In many cases these isoforms appear to be the underlying cause of the disease, while in others they may be induced in response to cardiovascular pathologies. Regardless of this, the detection of alternate splicing events in the heart can serve as useful diagnostic or prognostic tools, while those splicing events that seem to play a causative role in cardiovascular disease make attractive future drug targets.
publisher	MDPI
publishDate	2015
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661875/
_version_	1613506924560515072

Abnormalities in Alternative Splicing of Apoptotic Genes and Cardiovascular Diseases

Similar Items